QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 biocardia-regains-compliance-with-nasdaq-listing-requirements

BioCardia, Inc. (NASDAQ:BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pu...

 hc-wainwright--co-reiterates-buy-on-biocardia-maintains-25-price-target

HC Wainwright & Co. analyst Joseph Pantginis reiterates BioCardia (NASDAQ:BCDA) with a Buy and maintains $25 price target.

 biocardia-prices-public-offering-of-48m-shares-and-warrants-at-a-combined-price-of-125-for-up-to-12m-in-gross-proceeds

BioCardia®, Inc. (NASDAQ:BCDA) ("BioCardia" or the "Company"), a developer of cellular and cell-derived therape...

 biocardia-announces-primary-endpoint-results-of-open-label-roll-in-cohort-of-cardiamp-cell-therapy-in-chronic-myocardial-ischemia-trial

BioCardia, Inc. (NASDAQ:BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pu...

 biocardia-inc-files-for-offering-of-up-to-28m-shares-of-common-stock-together-with-up-to-28m-common-warrants

- SEC Filing

 biocardia-q2-eps-040-beats-050-estimate

BioCardia (NASDAQ:BCDA) reported quarterly losses of $(0.40) per share which beat the analyst consensus estimate of $(0.50) by ...

 biocardia-provides-expected-timing-for-regulatory-activities-for-fda-and-japan-pmda-approvals-of-its-cardiamp-cell-therapy-system-and-helix-transendocardial-delivery-catheter

Q3 2025 Helix application for approval to FDAThe Company intends to submit for approval of the Helix Transendocardial Delivery ...

 biocardia-submits-cardiamp-autologous-cell-therapy-investigational-heart-failure-treatment-for-clinical-consultation-with-japans-pharmaceuticals-and-medical-devices-agency

BioCardia®, Inc. (NASDAQ:BCDA), a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular a...

 biocardia-q1-eps-059-misses-039-estimate

BioCardia (NASDAQ:BCDA) reported quarterly losses of $(0.59) per share which missed the analyst consensus estimate of $(0.39) b...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION